日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study

在3b期SOLAR研究中,与比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺相比,卡博特韦+利匹韦林长效维持治疗12个月后,患者报告结局有所改善。

Mussini, Cristina; Cazanave, Charles; Adachi, Eisuke; Eu, Beng; Alonso, Marta Montero; Crofoot, Gordon; Chounta, Vasiliki; Kolobova, Irina; Sutton, Kenneth; Sutherland-Phillips, Denise; Urbaityte, Rimgaile; Ehmann, Alice; Scherzer, Jenny; de Los Rios, Patricia; D'Amico, Ronald; Spreen, William; van Wyk, Jean

Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide

长效卡博特韦和利匹韦林或比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺对体重和代谢的影响

Tan, Darrell H S; Antinori, Andrea; Eu, Beng; Galindo Puerto, María José; Kinder, Clifford; Sweet, Donna; Van Dam, Cornelius N; Sutton, Kenneth; Sutherland-Phillips, Denise; Berni, Alessandro; Zhang, Feifan; Urbaityte, Rimgaile; Baugh, Bryan; Spreen, William; van Wyk, Jean; Garges, Harmony P; Patel, Parul; Batterham, Rachel; D'Amico, Ronald

1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women

1550. 通过优化新型实施策略,让黑人女性参与卡博特韦长效制剂暴露前预防(EBONI)研究:医护人员对卡博特韦长效制剂用于顺性别和跨性别黑人女性暴露前预防的适用性的看法

Alabdulla, Majid; Wadoo, Ovais; Iqbal, Yousaf; Chandrappa, Nirvana Swamy Kudlur; Chandra, Prem; Masoodi, Naseer Ahmed; Al-Maslamani, Muna A Rahman S; Latoo, Javed; Werner, Nicole; Richmond, Teriya; Dunn, Michael; Bernard, Marye; Urbaityte, Rimgaile; Sutton, Kenneth; Sutherland-Phillips, Denise; Dyson, Alftan; Merrill, Deanna; Chang, Samantha; Mack, Nicole; Haley, Amber; Brown, Kimberley; Evans, Tammeka